Novavax Inc (NVAX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $10.11 (+1.10%), Market cap $1.49B, 52-week low–high $6.22 ~ $11.19.
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Financial statements, price targets, institutional (13F) holdings and related news for Novavax Inc are updated in real time on BlackAll Trade.
Novavax Inc trades at $10.11 (+1.10%). Real-time quotes and charts are available on BlackAll Trade.
Novavax Inc has a market cap of about $1.49B.
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationall